Media Articles Related to Xolair (Omalizumab)
Xolair® improves rate of severe asthma exacerbations
Source: Doctors Lounge - Chest Diseases
Xolair reduced the rate of hospital emergency visits by 44% in patients with inadequately controlled asthma.
Assessing Asthma in Kids: What Tools Work?
Source: Medscape Allergy & Clinical Immunology Headlines [2017.03.15]
Dr William Basco comments on a comprehensive review of objective and subjective evaluation tools for childhood asthma.
Asthmatics less able to fight off flu
Source: Respiratory / Asthma News From Medical News Today [2017.03.13]
People with asthma are likely to have worse symptoms when they get the flu because they have weaker immune systems, new Southampton research has shown..
Mite-Proof Bedding May Help Curb Asthma Attacks: Study
Source: MedicineNet Allergy Specialty [2017.03.10]
Title: Mite-Proof Bedding May Help Curb Asthma Attacks: Study
Category: Health News
Created: 3/10/2017 12:00:00 AM
Last Editorial Review: 3/10/2017 12:00:00 AM
New technique removes the cause of allergic asthma: Antibodies are suctioned off
Source: Allergy News From Medical News Today [2017.03.07]
Allergies are the commonest cause of asthma. The immune system over-reacts to harmless substances such as birch or grass pollen, for example, forming immunoglobulin E antibodies (IgE).
Published Studies Related to Xolair (Omalizumab)
Immunologic effects of omalizumab in children with severe refractory atopic
dermatitis: a randomized, placebo-controlled clinical trial. 
mediated by the TSLP pathway in young patients with severe refractory AD... CONCLUSIONS: Anti-IgE therapy with omalizumab decreases levels of cytokines that
Population-based efficacy modeling of omalizumab in patients with severe allergic
asthma inadequately controlled with standard therapy. 
Omalizumab, a recombinant humanized monoclonal antibody, is the first approved
anti-immunoglobulin E (IgE) agent for the treatment of subjects with moderate to
severe persistent allergic asthma that are inadequately controlled by the
standard of care... In addition, the resulting population models could be used to predict
population FEV1 or FeNO response for omalizumab and/or other anti-IgE
therapeutics for which PK-IgE models are constructed.
Omalizumab is effective in allergic and nonallergic patients with nasal polyps
and asthma. 
omalizumab in patients with nasal polyps and comorbid asthma... CONCLUSION: Omalizumab demonstrated clinical efficacy in the treatment of nasal
Omalizumab and the risk of malignancy: results from a pooled analysis. 
pooled data from clinical trials of omalizumab-treated patients... CONCLUSIONS: In this pooled analysis no association was observed between
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. [2011.09]
BACKGROUND: Proof-of-concept studies with omalizumab in patients with chronic idiopathic urticaria (CIU) have shown significant decreases in mean urticaria activity scores (UASs). OBJECTIVE: We sought to evaluate the efficacy and safety of omalizumab in patients with CIU who remain symptomatic despite concomitant H(1)-antihistamine therapy... CONCLUSION: This study demonstrated that a fixed dose of 300 or 600 mg of omalizumab provides rapid and effective treatment of CIU in patients who are symptomatic despite treatment with H(1)-antihistamines. Copyright (c) 2011 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
Clinical Trials Related to Xolair (Omalizumab)
Efficacy and Safety of Omalizumab in Bullous Pemphigoid [Completed]
The primary objective is to test the safety and efficacy of Xolair in the treatment of the
autoimmune blistering disease, bullous pemphigoid (BP).
This is a pilot, open label case-control study. Patients treated with Xolair will be
compared to patients receiving standard treatment with prednisone.
The enrollment period for the study is 24 weeks: 16 weeks active treatment and 8 additional
weeks of observation.
OIT and Xolair� (Omalizumab) in Cow's Milk Allergy [Active, not recruiting]
Food allergy affects up to 4% of the U. S. population and is most common in young children.
Milk allergy is the most common cause of food allergy in infants and young children, and
usually develops in the first year of life. There is no treatment for food allergy and the
current standard of care for milk-allergic individuals is the avoidance of milk-containing
products. Research is underway to identify potential therapeutic strategies to reduce or
eliminate the adverse effects experienced by milk-allergic individuals when they consume
Several studies have suggested that milk-allergic children who receive milk protein oral
immunotherapy (OIT) may become desensitized to milk, resulting in short term protection
against accidental ingestion of milk products. However, these children did not develop
"tolerance," which is long term protection even after milk immunotherapy is stopped. A
potential strategy to induce tolerance to milk uses milk in combination with Xolair®
(omalizumab). Xolair consists of anti-IgE molecules that attach to IgE, the major antibody
involved in allergic reactions. The goal of this clinical trial is to see whether Xolair®
in combination with milk protein OIT is safer and more effective than OIT alone in inducing
tolerance to milk and milk products. Participants will be administered a double blind,
placebo controlled milk challenge at various time points in the study. If desensitization is
achieved participants will be tested for tolerance at a certain time point after stopping
Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair [Completed]
The purpose of this study is to study the effects of Xolair using non-invasive techniques
from the expired gas of patients with moderate to severe allergic asthma.
The Effect of Xolair (Omalizumab) on Allergy Blood Cells [Completed]
We are studying Xolair (omalizumab) to see it's effect on allergic blood cells. The blood
tests will be done in a test tube to see if they react differently before and after
treatment. The blood cells will be mixed with to whatever the person is allergic.
A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA) [Completed]
This is a multicenter, randomized, double-blind, placebo-controlled study of the efficacy,
safety, and tolerability of subcutaneously administered Xolair as add-on therapy for the
treatment of subjects aged 12-75 years old diagnosed with moderate to severe asthma who are
inadequately controlled with high-dose inhaled corticosteroids (ICS)+ long-acting
beta-agonists (LABA) with or without additional controller therapy.
Reports of Suspected Xolair (Omalizumab) Side Effects
Blood Pressure Increased (178),
Headache (169), more >>